Drug intelligence / Profile preview

ActiPhen

Development stage: Unknown
Lead developer: RDC Rafael Development
Administration: Oral

Overview

ActiPhen is a proprietary gold kiwifruit (*Actinidia chinensis*) extract developed by RDC Global Pty Ltd, specifically designed to support gastrointestinal health. It is standardized for its content of actinidin, a natural proteolytic enzyme that assists in the breakdown of proteins in the digestive tract, and contains dietary fiber and polyphenols. Clinical studies, including a randomized, double-blind, placebo-controlled trial in healthy adults, have evaluated its efficacy in improving bowel function, reducing bloating, and alleviating symptoms of gastrointestinal dysfunction. As a natural plant-derived product, it is primarily positioned as a nutraceutical or functional food ingredient for digestive regularity.

Brand names: ActiPhen
Other names: Gold kiwifruit extractActinidia chinensis extract

Beyond the preview

Go deeper on ActiPhen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ActiPhen.

Explore the full profile